Does pI3K-mTOR pathway inhibition exhibit efficacy against high-grade glioma in clinically relevant mouse models?
PI3K/mTOR-inhibitors with weak affinities for ABC-transporters can achieve target inhibition in brain (tumors), but have modest single agent efficacy and combinations with (BBB penetrable) inhibitors of other activated pathways may be required.
Lack of smooth muscle cells in the aneurysm wall promotes wall degradation, aneurysm growth and rupture, even if the aneurysm is occluded by luminal thrombus. Transplantation of smooth muscle cells into the luminal thrombus can reduce this degenerative remodeling.